Details of the Drug
General Information of Drug (ID: DM94LID)
Drug Name |
1-(2-Fluoro-phenyl)-piperazine
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
1-(2-Fluorophenyl)piperazine; 1011-15-0; Piperazine, 1-(2-fluorophenyl)-; 1-(2-Fluorophenyl)-piperazine; 1-(2-Fluoro-phenyl)-piperazine; CHEMBL9429; IVTZRJKKXSKXKO-UHFFFAOYSA-N; 1-(2-Fluorophenyl)piperazine, 97%; MFCD00040726; (2-fluorophenyl)piperazine; EINECS 213-780-4; oFPP; PubChem8573; 1-(2-fluorophenyl)piperazinehydrochloride; 2-fluorophenylpiperazine; 2-Fluorophenyl piperazine; ACMC-1BX8H; ortho-fluorophenylpiperazine; 4-(fluorophenyl)piperazine; AC1Q4O5O; AC1Q4L3C; AC1L2EA5; 1-(2-flurophenyl)piperazine
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure | |||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 180.22 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | 1.5 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 1 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 1 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 3 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
|||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | ||||||||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||